Eledon Pharmaceuticals (Nasdaq: ELDN) presented updated data from its Phase 2 BESTOW extension study at the International Congress of The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE